NextCure, Inc.(NXTC)

Description: NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.

---

Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Solid Tumors Tumor Immunotherapy Cancer Treatment Clinical Development Non Small Cell Lung Cancer Ovarian Cancer Virotherapy Small Cell Lung Cancer Oncolytics Biotech Treatment Of Ovarian Cancer Metastasis Metastatic Solid Tumors Renal Cancer Tumor Microenvironment Immune Related Diseases Halozyme

---

Home Page: www.nextcure.com

NXTC Technical Analysis

9000 Virginia Manor Road
Beltsville, MD 20705
United States
Phone: 240 399 4900

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)